For Eleven Biotherapeutics, Cancer Trial Outcomes Could Be 'Major Catalyst'

Eleven Biotherapeutics, Inc. EBIO, a Cambridge, Massachusetts-based developer of targeted protein therapeutics, has been showing promising clinical data for TPT-based cancer treatments.

The stock could see significant upside if later-stage bladder cancer trials set for mid-2018 prove to be successful, according to H.C. Wainwright & Co.

The Analyst

Analyst Swayampakula Ramakanth initiated coverage of Eleven Bio with a Buy rating and $2 price target.

The Thesis

Eleven Bio’s Vicinium TPT has displayed safety and efficacy in multiple bladder cancer studies and is being evaluated through a Phase 3 VISTA study, which could prove to be a pivotal step in bladder cancer treatment, Ramakanth said in a Monday note.

“We believe the upcoming release of results from the VISTA study could be a major catalyst for the stock.”

Vicinium, like other TPTs, provides lower immunogenicity and better stability and tumor penetration, the analyst said. 

In previous Phase 1 and 2 studies, Vicinium was well-tolerated, demonstrated no dose-limiting toxicities and achieved a response rate of approximately 40 percent at three months, Rakamanth said. 

Price Action

Eleven Bio was trading up 7.6 percent at $1.13 at the time of publication Tuesday.

Related Links: 

7 Biotech Stocks With Clinical Trial Outcomes In March

Cantor Fitzgerald Names 8 Upcoming Biotech Catalysts

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorBiotechPrice TargetInitiationAnalyst RatingsGeneralbladder cancerHC WainwrightSwayampakula Ramakanthtargeted protein therapeutics
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!